In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

LifeMax gains global license to Novartis' BPR277 for Netherton syndrome

Executive Summary

LifeMax Healthcare International Corp.'s US subsidiary LifeMax Laboratories Inc. secured an exclusive worldwide license to develop, manufacture, and commercialize Novartis Pharma AG's BPR277, a topical ointment in development for Netherton syndrome, a rare genetic disorder affecting the skin, hair, and immune system.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies